Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last --
Change Today 0.00 / 0.00%
Volume 0.0
4589 On Other Exchanges
Symbol
Exchange
4589 is not on other exchanges.
All times are local (Market data is delayed by at least 15 minutes).

acucela inc (4589) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
0.0
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ACUCELA INC (4589)

Related News

No related news articles were found.

acucela inc (4589) Related Businessweek News

No Related Businessweek News Found

acucela inc (4589) Details

Acucela Inc., a biotechnology company, discovers and develops therapeutic products to treat and slow the progression of sight-threatening ophthalmic diseases worldwide. The company’s clinical stage product candidates include Emixustat hydrochloride, which is in Phase IIb/III clinical trial for the treatment of geographic atrophy associated with dry age-related macular degeneration; and OPA-6566, an adenosine A2a receptor agonist that has completed Phase I/II clinical trial for the treatment of glaucoma. It has a co-development and collaboration agreement with Otsuka Pharmaceutical Co., Ltd. for Emixustat and OPA-6566. The company was founded in 2002 and is headquartered in Seattle, Washington.

49 Employees
Last Reported Date: 03/30/15
Founded in 2002

acucela inc (4589) Top Compensated Officers

Founder, Chairman, Chief Executive Officer an...
Total Annual Compensation: $492.3K
Vice President of Human Resources
Total Annual Compensation: $263.4K
Compensation as of Fiscal Year 2014.

acucela inc (4589) Key Developments

Acucela Hires Roger Girard as Chief Strategy Officer, Effective September 1, 2015

The Acucela Board of Directors appointed Girard as Chief Strategy Officer, effective Sept. 1, 2015, at its July 2 meeting in Tokyo, Japan. He most recently served as Chief Financial Officer and Co-Founder of CareCap and as CEO of Neuro-ID. Girard also previously served as Chairman and CEO of IsoRay Medical.

Acucela Inc. Announces Resignation of Dewey Blocker as Vice-President of Finance and Secretary Effective July 31, 2015

On June 16, 2015, Dewey Blocker, Jr., vice-president of finance and secretary of Acucela Inc. announced his resignation from the company effective July 31, 2015.

Acucela Inc. Announces Publication of Phase 2a Clinical Trial Results for Emixustat Hydrochloride

Acucela Inc. announced the publication of results from a Phase 2a clinical trial of emixustat hydrochloride (emixustat) in patients with geographic atrophy (GA) associated with dry age-related macular degeneration (AMD) in the June online edition of RETINA:The Journal of Retinal and Vitreous Diseases. The lead author on the paper is Pravin U. Dugel, MD, Managing Partner, Retinal Consultants of Arizona and Clinical Professor, USC Eye Institute, Keck School of Medicine, University of Southern California. He was also a principal investigator of the emixustat study. Emixustat, the first internally developed compound by Acucela, is orally dosed, targets the visual cycle, and is in development for the potential treatment of GA associated with dry AMD for which there is currently no U.S. Food and Drug Administration (FDA)-approved therapy available.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4589:JP ¥720.00 JPY -7.00

4589 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4589.
View Industry Companies
 

Industry Analysis

4589

Industry Average

Valuation 4589 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 6.5x
Price/Book 1.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACUCELA INC, please visit www.acucela.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.